Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference [Accessibility Statement] Skip NavigationBOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The Company will host a lunch forum with experts presenting Becke ...

OAK BROOK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Hub Group, Inc. (Nasdaq: HUBG) today announced that it has filed a Notification of Late Filing on Form 12b-25 with the U.S. Securities and Exchange Commission ("SEC") and will be delayed in filing its Annual Report on Form 10-K for the year ended December 31, 2025. The extension is required to allow additional time to finalize the Company's financial results for the fourth quarter and full year 2025. As previously announced, the Company plans to restate it ...

Presentation at THT 2026 Atrioventricular Interval Modulation Therapy: A Device-Based Therapy for Hypertension and Diastolic Heart Failure (Tuesday, March 3, 2026, at 10:20am ET) NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two presentations that wil ...

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed t ...

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision- making save time and money. RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix). PBPK modeling ...

Dividend Kings is offering a special promotion this March. All new users who join will be entered into a drawing to only pay $1 for their first year. Start with our $30 month long trial, pay for your annual membership of $699, and you're entered! One new or returning subscriber will be picked and refunded $698. Kody's Dividends, Justin Law, and Rachel Kaufman are part of the Dividend Kings team. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is be ...

About Orchestra BioMed Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company's two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market oppor ...

CoreWeave ( CRWV ) reported Q4 earnings after the bell on Thursday. The stock was initially down roughly 2% as soon as the print came out, but by the end of trading on Friday, the drop reached as much Tech Stock Pros is a team of three former technology sector engineers with a long history of investing in the tech sector. They run Tech Contrarians, an investing group providing institutional-level company research to individual investors. Utilizing a live portfolio with quarterly updates, bi-weekly newslette ...

Agreement with Imperial Imaging strengthens Nanox's commercial rollout across the orthopedic-rich segment in six U.S. Southeast states. Distribution Agreement Supports U.S. Market Expansion PETACH TIKVA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its US-based subsidiary, Nanox Impact Inc. has signed a new distribution agreement with Imperial Imaging Technology LLC, a Georgia based provider of diagnost ...

Transformational Leader Bryan Ganz to Retire as CEO Conn Davis Appointed as Successor TJ Kennedy Appointed Chair of the Board ANDOVER, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. ("Byrna" or the "Company") (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that Bryan Ganz is retiring as Chief Executive Officer and as a member of the Company's Board of Directo ...